Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 vs Tislelizumab in First-Line Advanced Squamous Non-Small Cell Lung Cancer
NCT07416474Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of RC148 in squamous cell carcinoma of the lung (SCCL), sponsored by RemeGen. Started Apr 2026; status: recruiting.
02
Drugs
RC148
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07416474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416474.